[
  {
    "chunk_id": "rr6210_chunk_0",
    "document_id": "rr6210",
    "text": "[Section: 0.5\nNA\nNA]\n≥20 \n10\n1\n20\n1\n20\n1\nHemodialysis patients and other immunocompromised persons\n<20¶\n5\n0.5\n10",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "0.5\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 0,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_1",
    "document_id": "rr6210",
    "text": "[Section: 2\nNA\nNA]\nAbbreviation: NA = not applicable. \n\t *\tSingle-antigen vaccine is usually administered on a 3-dose schedule at 0, 1, and 6 months. Other schedules are available. See package insert. \n\t †\tCombined hepatitis A and hepatitis B vaccine is recommended for persons  aged ≥18 years at increased risk for both hepatitis B virus and hepatitis A virus infections. \n\t §\tAdult formulation administered on a 2-dose schedule. \n\t ¶\tHigher dosages might be more immunogenic, but no specific recommendations have been made. \n\t**\tDialysis formulation administered on a 3-dose schedule at 0, 1, and 6 months. \n\t††\tTwo 1 mL doses administered at one site on a 4-dose schedule at 0, 1, 2, and 6 months. \nT\nh\nis\n f\nig\nur\ne \nis\n \na li\nne g\nraph\n tha\nt pr\ne\nsents the probability of HBV infection among",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 1,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_2",
    "document_id": "rr6210",
    "text": "T\nh\nis\n f\nig\nur\ne \nis\n \na li\nne g\nraph\n tha\nt pr\ne\nsents the probability of HBV infection among\n HCP \ntrainees\n on the bas\nis of p\nrevalence of \nHBsAg-positivity of sou\nrce patients and approach to assessment.\nFIGURE 4. Hepatitis B virus infection rate among health-care personnel trainees, by prevalence \nof hepatitis B surface antigen positivity of source patients and approach to assessment\nSource: Personal communication. Hoerger TJ, Ludlow-Bradley C. Durham, North Carolina: Research \nTriangle Institute, International; 2012.\n*\tPer 100,000 population of health-care personnel. \nRecommendations and Reports\n8\t\nMMWR  /  December 20, 2013  /  Vol. 62  /  No. 10\nResponse to a Challenge Dose of Vaccine\nTo assess vaccine response in remotely vaccinated HCP, a",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 2,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_3",
    "document_id": "rr6210",
    "text": "Response to a Challenge Dose of Vaccine\nTo assess vaccine response in remotely vaccinated HCP, a \nchallenge dose of HepB vaccine can be used to determine \nthe presence of vaccine-induced immunologic memory \nthrough generation of an anamnestic response. The term \n“booster dose” has been used to refer to a dose of HepB vaccine \nadministered after a primary vaccination series to provide \nrapid protective immunity against significant infection (i.e., \ninfection resulting in serologic test results positive for HBV \nand/or clinically significant disease) (40). Among persons \nvaccinated 5.9–17.5 years previously at age <1 year who have \nanti-HBs levels <10 mIU/mL, approximately 60.0%–97.4% \nshowed a response to a single challenge dose of HepB vaccine",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 3,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_4",
    "document_id": "rr6210",
    "text": "showed a response to a single challenge dose of HepB vaccine \ndemonstrating protective levels of anti-HBs ≥10 mIU/mL \n(50–54). Among persons vaccinated 9–22 years previously at \nage ≥1 year who have anti-HBs levels <10 mIU/mL, 69.2%–\n96.4% showed a response to a single challenge dose of HepB \nvaccine demonstrating protective levels of anti-HBs ≥10 mIU/\nmL (41,54,60,62). The proportion of responders to a challenge \ndose might vary by population and age at receiving the primary \nHepB series. HCP with a response ≥10 mIU/mL following a \nchallenge dose are considered protected, regardless of future \ndeclines in anti-HBs. Conclusions about the response to a \nchallenge dose are made on the basis of relatively few studies \nand might change as additional data become available.",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 4,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_5",
    "document_id": "rr6210",
    "text": "and might change as additional data become available.\nDuration of Vaccine Protection among \nResponders\nAmong immunocompetent HepB vaccine responders, studies \nsuggest protection against acute symptomatic and chronic \nhepatitis B infection persists for ≥22 years (9,15,40). Three \ncohort studies that monitored 1,006 subjects for ≥20 years \nhave been informative (41,63,64). In two of the cohorts from \nareas with high HBV endemicity, new chronic HBV infections \nwere documented in 0.8% (0 and 1.0%) of 513 (109 and 404) \nsubjects, respectively, who responded or presumably responded \nto HepB vaccination starting at birth (63,64). Approximately \n20% of subjects had evidence of natural boosting of anti-HBs, \npresumably from exposure to HBV (63,64). A third cohort",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 5,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_6",
    "document_id": "rr6210",
    "text": "presumably from exposure to HBV (63,64). A third cohort \nof 493 subjects in an area with intermediate HBV endemicity \nreceived HepB vaccination between ages 6 months and \n≥50 years (41). Among vaccine responders, no acute or chronic \nHBV was detected, although 1% of subjects experienced \nsubclinical HBV infection without chronic infection during \n≥20 years of follow-up (41). The significance of subclinical \nbreakthrough HBV infection without chronic HBV and \ntransient HBV infection is unknown.\nHepB Vaccination and Postvaccination Testing \namong HCP\nThe Bloodborne Pathogens Standard issued in 1991 by \nOSHA mandates that HepB vaccination be made available \nat the employer’s expense to employees who have reasonably \nanticipated skin, eye, mucous membrane, or parenteral contact",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 6,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_7",
    "document_id": "rr6210",
    "text": "anticipated skin, eye, mucous membrane, or parenteral contact \nwith blood or other potentially infectious materials that might \nresult from the performance of an employee’s duties (27). \nHepB vaccination coverage data obtained through the National \nHealth Interview Survey (NHIS) in 2011 demonstrated \n≥3-dose coverage of 63.8% among HCP aged ≥19 years \n(23). NHIS 2010 data demonstrated ≥3-dose coverage of \n74% for HCP with direct patient contact, and 46% for HCP \nwithout direct patient contact (65), substantially below the \nHealthy People 2020 target of 90% HepB vaccination coverage \namong HCP (objective no. IID-15.3) (66).\nPostvaccination serologic testing for anti-HBs is recommended \n1–2 months after the last vaccine dose for HCP at risk for",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 7,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_8",
    "document_id": "rr6210",
    "text": "1–2 months after the last vaccine dose for HCP at risk for \noccupational percutaneous or mucosal exposures (11). During \n2012, a survey was administered to 389 California acute care \nhospitals or centers comprised of more than one hospital \nto assess current practices for ensuring HCP protection \nagainst HBV. Hospitals were identified from a listserv of 580 \ninfection prevention and employee health staff (67). Responses \nThis figure is a graph that present\ns evidence of protection from h\ne\npa\nti\nti\ns \nB \nvi\nru\ns \non\n th\ne\n \nba\nsi\ns \nof years since vaccination, in 5-year increments, measured by the proportion of persons with anti-HBs  ≥10 mIU/mL.\nSources: Samandari T, Fiore AE, Negus S, et al. Differences in response to a",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 8,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_9",
    "document_id": "rr6210",
    "text": "Sources: Samandari T, Fiore AE, Negus S, et al. Differences in response to a \nhepatitis B vaccine booster dose among Alaskan children and adolescents \nvaccinated during infancy. Pediatrics 2007;120:e373–81. Petersen KM, Bulkow LR, \nMcMahon BJ, et al. Duration of hepatitis B immunity in low risk children receiving \nhepatitis B vaccinations from birth. Pediatr Infect Dis J 2004;23:650–5. \nHammitt LL, Hennessy TW, Fiore AE, et al. Hepatitis B immunity in children \nvaccinated with recombinant hepatitis B vaccine beginning at birth: a follow-up \nstudy at 15 years. Vaccine. 2007;25:6958–64. Dentinger CM, McMahon BJ, \nButler JC, et al. Persistence of antibody to hepatitis B and protection from disease \namong Alaska natives immunized at birth. Pediatr Infect Dis J 2005;24:786–92.",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 9,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_10",
    "document_id": "rr6210",
    "text": "among Alaska natives immunized at birth. Pediatr Infect Dis J 2005;24:786–92. \nMiddleman AB, Baker C, Hu DJ, et al. Duration of immunity from hepatitis B \nvaccine administered soon after birth among 16 to 19 year old youth in the \nUnited States. Presented to the Pediatric Academic Societies, Boston, MA, \nApril 29, 2012.\n*\tIncludes U.S. studies only.\nFIGURE 5. Serologic evidence of protection, by years since vaccination \namong persons vaccinated at age <1 year*\nRecommendations and Reports\nMMWR  /  December 20, 2013  /  Vol. 62  /  No. 10\t\n9\nwere obtained from 153 listserv subscribers, comprising \napproximately 39% of hospitals (67). Responding hospitals \nwere not representative of all hospitals in the United States \n(67). Of the 153 responding hospitals, most (92 [60.1%])",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 10,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_11",
    "document_id": "rr6210",
    "text": "(67). Of the 153 responding hospitals, most (92 [60.1%]) \nwere nongovernment not-for-profit community hospitals, \nfollowed by investor-owned (for-profit) community hospitals \n(32 [20.9%]), and state and local government community \nhospitals (13 [8.5%]) (67). One fourth (37 [24.2%]) were \nteaching hospitals (67). Responding hospitals had between 35 \nand 15,421 (median: 1,000) HCP with reasonably anticipated \nrisk for blood or body fluid exposure (67). The majority \nof respondents (71.9%) indicated current practices at their \ninstitution consist of measuring anti-HBs on a pre-exposure \nbasis, followed by HepB vaccination if anti-HBs is <10 mIU/mL \n(67). A smaller proportion of respondents (15.7%) indicated \ntheir institution follows an approach relying upon postexposure",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 11,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_12",
    "document_id": "rr6210",
    "text": "their institution follows an approach relying upon postexposure \nmanagement (67). Postvaccination anti-HBs results were known \nfor approximately 69% of HCP at these facilities (67).\nRevaccination for Vaccine Nonresponse\nRevaccination with ≥1dose of HepB vaccine for nonresponse \nsubsequent to the primary series increases the proportion of \npersons achieving vaccine-induced seroprotection (15). Among \n178 persons with occupational risk for HBV infection, 47% \nof those without protective antibody levels after a primary \nvaccination series developed vaccine-induced seroprotection \nafter one additional dose of HepB vaccine (6). An estimated \n42% of 86 persons without protective anti-HBs levels after \nthe first revaccination dose and who received 2 additional",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 12,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_13",
    "document_id": "rr6210",
    "text": "the first revaccination dose and who received 2 additional \ndoses developed protective levels of anti-HBs representing a \ncumulative response rate of 69% among initial nonresponders \nafter 3 revaccination doses (6). Persons who have measurable \nbut low (i.e., 1–9 mIU/mL) levels of anti-HBs after the initial \nseries have better response to revaccination than persons who \nhave no measurable anti-HBs (36,62,68,69).\nSingle dose revaccination with a higher dosage has not been \ndemonstrated to increase the proportion of healthy adult \nnonresponders (70,71) or previous responders revaccinated as part \nof a clinical trial (62) who achieve vaccine-induced seroprotection. \nHowever, 3-dose revaccination with a higher dosage (40 µg) did \nimprove the proportion of nonresponders achieving anti-HBs",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 13,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_14",
    "document_id": "rr6210",
    "text": "improve the proportion of nonresponders achieving anti-HBs \nlevels of ≥10 mIU/mL in one study (100% among 17 persons \nreceiving 40 µg dose versus 62.5% among 18 persons receiving \n10 µg dose, p = 0.015, Fisher’s exact test) (70). Revaccination with \n>3 doses (i.e., >6 total doses) is not recommended (11).\nHBV Infection among Vaccinated and \nUnvaccinated HCP\nFrom 1983 to 2010, the number of HBV infections among \nHCP declined approximately 98%, from an estimated 17,000 \ninfections to 263 acute HBV infections (considering that \noccupational history was assessed for 43.6% of cases and using \na correction factor of 10.5 to account for underreporting and \nasymptomatic infection) (10). The decrease in acute HBV \ninfection among HCP probably resulted from routine pre-",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 14,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_15",
    "document_id": "rr6210",
    "text": "infection among HCP probably resulted from routine pre-\nexposure HepB vaccination and reduced risk for exposure \nthrough improvements in infection-control practices (28,72,73).\nAlthough few studies have evaluated the vaccination history \nof persons with acute hepatitis B (74), some cases of acute \nhepatitis B and chronic HBV infection can be expected in \nunvaccinated persons and among vaccine nonresponders. \nDuring 2005–2010, a total of 203 cases of persons with acute \nhepatitis B among HCP were reported to CDC’s National \nNotifiable Diseases Surveillance System (NNDSS) (75). Six of \n17 patients with information on the development of chronic \nHBV infection developed chronic HBV infection (75). \nFollow-up of 67 (76.1%) of 88 HCP initially reported as having",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 15,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_16",
    "document_id": "rr6210",
    "text": "Follow-up of 67 (76.1%) of 88 HCP initially reported as having \na positive or unknown HepB vaccination history indicated that \n35 HCP reported vaccination with ≥3 HepB vaccine doses \n(seven had documentation to support the reported vaccination \nhistory) (75). Among the 35 HCP reporting vaccination with \n≥3 HepB vaccine doses, one HCP demonstrated an immune \nresponse (i.e., anti-HBs ≥10 mlU/mL); the remaining 34 were \nnonresponders or had an unknown response status (75). Four \nof eight HCP with ≥3-dose HepB vaccination with information \ndeveloped chronic HBV infection; none of the four had complete \ndocumentation of ≥3 HepB vaccine doses (75). Postvaccination \nserologic testing was available for only one of seven HCPs with \ndocumentation of ≥3-doses of HepB vaccine; this HCP had",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 16,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_17",
    "document_id": "rr6210",
    "text": "documentation of ≥3-doses of HepB vaccine; this HCP had \nan anti-HBs level <10 mIU/mL after 4 doses of vaccine (75).\nAlthough reported data did not enable identification of the \nmodes of transmission or information on receipt of postexposure \nprophylaxis, 28 (16.7%) of 168 HCP for whom data were \navailable reported an accidental stick or puncture with a \nneedle or other object contaminated with blood during the \n6 weeks through 6 months before illness, possibly representing \noccupational acquisition of infection (75). Unrecognized \nexposures might have resulted in HBV infections among HCP \nwho did not report an exposure (2). Other risk factors for \nHBV exposure in the 6 weeks through 6 months before illness \n(i.e., injection drug use, men who have sex with men, multiple",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 17,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_18",
    "document_id": "rr6210",
    "text": "(i.e., injection drug use, men who have sex with men, multiple \nsex partners, contact with a hepatitis B case, dialysis patient, \nreceipt of blood transfusion, surgery, acupuncture, and tattoo \nreceipt) were present among 121 (59.6%) of 203 HCP, possibly \nsuggesting their exposures were not occupational (75).\nManaging HCP Vaccination and Serologic \nTest Results\nImmunization information systems (IIS) provide consolidated \nvaccination histories for use by vaccination providers in \nRecommendations and Reports\n10\t\nMMWR  /  December 20, 2013  /  Vol. 62  /  No. 10\ndetermining appropriate vaccinations (76). Accessing IIS for \nvaccination records might decrease unnecessary revaccination \namong HCP who no longer have records of HepB vaccination.",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 18,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_19",
    "document_id": "rr6210",
    "text": "among HCP who no longer have records of HepB vaccination. \nIIS do not accept postvaccination anti-HBs test results (77). To \nreduce the cost and inconvenience of repeat anti-HBs testing \nwhen HCP are employed by different health-care facilities, \nCDC recommends that institutions consider systems for \nlong-term management of anti-HBs and other hepatitis B \nserologic test results. Mechanisms for tracking vaccination \nand hepatitis B serologic test results in health information \ntechnology products could also reduce cost and inconvenience \nof repeat anti-HBs testing.\nPassive Prophylaxis of HBV Exposed \nHealth Care Personnel\nHepatitis B immune globulin\nHepatitis B immune globulin (HBIG) provides passive \nanti-HBs and temporary (i.e., 3–6 months) protection (15).",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 19,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_20",
    "document_id": "rr6210",
    "text": "anti-HBs and temporary (i.e., 3–6 months) protection (15). \nHBIG is prepared from human plasma known to contain a \nhigh titer of anti-HBs. HBIG is typically used together with \nHepB vaccine for postexposure prophylaxis (15). For persons \nwho do not respond to HepB vaccine, HBIG administered \nalone is the primary method of protection after HBV exposure \n(15). The standard adult dose of HBIG is 0.06 mL/kg. HBIG \nis administered by intramuscular injection; an appropriate \nmuscle mass (i.e., deltoid or gluteal) should be chosen in which \nto deliver the large volume of HBIG required and a needle \nlength appropriate for the HCP’s size should be used. HBIG \ncan be administered simultaneously with HepB vaccine but \nat a different injection site (15).\nSafety",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 20,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_21",
    "document_id": "rr6210",
    "text": "at a different injection site (15).\nSafety\nThe plasma from which HBIG is prepared is screened for \nHBsAg, HCV, and HIV (15). The process used to prepare \nHBIG inactivates HBV, HCV, and HIV from the final product. \nNo evidence exists that HBV, HCV, or HIV has ever been \ntransmitted by HBIG thar is commercially available in the \nUnited States (15).\nSerious adverse effects from HBIG, when administered \nas recommended, are rare (1). Local pain and tenderness at \nthe injection site, urticaria, and angioedema might occur; \nanaphylactic reactions, although rare, have been reported \nfollowing the injection of human immune globulin (IG) \npreparations (1). HBIG is not contraindicated for pregnant \n(1,78) or lactating women (1).\nEfficacy\nThe effectiveness of HBIG and HepB vaccine in various",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 21,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_22",
    "document_id": "rr6210",
    "text": "(1,78) or lactating women (1).\nEfficacy\nThe effectiveness of HBIG and HepB vaccine in various \npostexposure settings has been evaluated by prospective \nstudies. For perinatal exposure to a mother positive for \nboth HBsAg and HBeAg, a regimen combining HBIG and \ninitiation of the HepB vaccine series at birth is 85%–95% \neffective in preventing HBV infection (79,80). Regimens \ninvolving either multiple doses of HBIG alone or the HepB \nvaccine series alone are 70%–75% effective in preventing \nHBV infection when administered shortly after exposure \n(81). In the occupational setting, multiple doses of HBIG \nstarting within 1 week following percutaneous exposure to \nHBsAg-positive blood provide an estimated 75% protection \nfrom HBV infection (82–86). Administration of HBIG might",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 22,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_23",
    "document_id": "rr6210",
    "text": "from HBV infection (82–86). Administration of HBIG might \nprolong the incubation period of HBV infection among \npersons who develop infection (82,85,87,88). A comparison \nof the postexposure efficacy of the combination of HBIG and \nthe HepB vaccine series or HBIG alone has not been evaluated \nin the occupational setting (1). Whether the increased efficacy \nof HBIG added to HepB vaccine observed in the perinatal \nsetting, compared with HBIG alone, applies to adults exposed \noccupationally remains unknown.\nCost-Effectiveness Considerations\nTo examine the cost-effectiveness of various strategies for \nassessing HCP protection from hepatitis B, two economic \nmodels that yielded calculations of the incremental cost per \nquality-adjusted life-year (QALY) saved were developed.",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 23,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_24",
    "document_id": "rr6210",
    "text": "quality-adjusted life-year (QALY) saved were developed. \nOne model represented an approach in which anti-HBs is \nmeasured on a pre-exposure basis, and HCP with anti-HBs \n<10 mIU/mL receive an additional dose of HepB vaccine, \nfollowed by repeat anti-HBs measurement. If anti-HBs \nremains <10 mIU/mL after the first revaccination dose, the \nHCP receives two additional revaccination doses of HepB \nvaccine followed by repeat anti-HBs measurement. Another \nmodel represented a postexposure management approach; \nat the time of exposure, the HCP is tested for anti-HBs and \nthe source patient is tested simultaneously for HBsAg, and \npostexposure prophylaxis would be administered on the basis \nof these results. Results from the two models were compared.",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 24,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_25",
    "document_id": "rr6210",
    "text": "of these results. Results from the two models were compared. \nA decision-tree analysis was used to combine all parameters \nand calculate the total intervention costs and probability of \ninfection. In addition, HBV infection-related costs and QALY \nloss (accounting for acute and asymptomatic infections and \na 6% probability of chronic infection) were determined from \nan existing model (89) and were considered for the HCP’s \nremaining lifetime. The intervention time frame included a \n1-year analysis and a multiyear analysis covering up to 10 years \nof exposure. A 3% annual discount rate was used, and all final \ncost figures were converted to 2010 U.S. dollars using the \nMedical Consumer Price Index.\nThe baseline cost-effectiveness models assumed that an ideal",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 25,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_26",
    "document_id": "rr6210",
    "text": "Medical Consumer Price Index.\nThe baseline cost-effectiveness models assumed that an ideal \n95% of HCP have initial and sustained protection against \nHBV infection after a primary ≥3-dose HepB vaccine series, \nRecommendations and Reports\nMMWR  /  December 20, 2013  /  Vol. 62  /  No. 10\t\n11\nirrespective of the presence of detectable anti-HBs. Ninety-five \npercent protection was derived from the proportion of persons \naged <40 years, including term newborns that have measurable \nanti-HBs ≥10 mIU/mL soon after a primary vaccination series. \nApproximately 18–25 years after vaccination, approximately \n20% of HCP (vaccinated at age <1 year) or approximately \n80% of HCP (vaccinated at age ≥1 year) retain anti-HBs \n≥10 mIU/mL. The model did not account for unrecognized",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 26,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_27",
    "document_id": "rr6210",
    "text": "≥10 mIU/mL. The model did not account for unrecognized \nexposures, as probability data for unrecognized exposures are not \navailable, or suboptimal vaccine coverage that exists among HCP.\nFor pre-exposure anti-HBs testing followed by revaccination \nand retesting, if necessary, compared with doing nothing, the \nincremental cost per QALY saved was $4,542,467 for trainees \nand $3,149,183 for nontrainees at year one, and decreased \nto $893,619 and $796,140, respectively, over 10 years. \nThis approach is expected to result in 3.7 and 1.6 visits to \noccupational health for trainees and nontrainees, respectively. \nThe expected number of infections is 0.7 per 100,000 and 0.4 \nper 100,000 for trainees and nontrainees, respectively. For an \napproach relying upon postexposure management, compared",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 27,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_28",
    "document_id": "rr6210",
    "text": "approach relying upon postexposure management, compared \nwith doing nothing, the incremental cost per QALY saved was \n$2,270,801 for trainees and $1,610,998 for nontrainees at year \none, and decreased to $917,859 and $1,114,364 respectively, \nover 10 years. The expected number of infections is 3.0 per \n100,000 and 1.7 per 100,000 for trainees and nontrainees, \nrespectively. Although an approach relying upon postexposure \nmanagement might be less costly per QALY saved initially for \nmany institutions, pre-exposure anti-HBs testing with possible \nrevaccination becomes more cost-effective compared with a \npostexposure approach over time.\nSensitivity analyses demonstrated that cost-effectiveness \nimproves in settings where a greater proportion of source",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 28,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_29",
    "document_id": "rr6210",
    "text": "improves in settings where a greater proportion of source \npatients are HBsAg-positive and among HCP with higher risk \nfor exposure (e.g., surgeons). Cost-effectiveness can change \nas new antivirals become available for treatment of HBV \ninfection. Vaccinating previously unvaccinated HCP trainees \nfollowed by postvaccination serologic testing, compared with \ndoing nothing, has an incremental cost per QALY saved of \n$374,646 at year one and $51,537 over 10 years, accounting \nfor direct costs to the health-care system and direct medical \ncosts of hepatitis B-related illness and complications.\nRecommendations\nPre-Exposure Management\nEducation and Infrastructure\nAt the time of hire or matriculation, health-care providers \nand health-care institutions should provide training to HCP",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 29,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_30",
    "document_id": "rr6210",
    "text": "and health-care institutions should provide training to HCP \nto improve recognition and encourage timely reporting of \nblood and body fluid exposures. The possibility that the \npostexposure evaluation will cause the HCP to have time lost \nfrom work should not be a barrier to reporting. Institutions \nshould ensure that HCP have rapid access to postexposure \ntesting and prophylaxis, including HBIG and HepB vaccine.\nSerologic Testing for HBV Infection\nTesting unvaccinated HCP for HBV infection is not generally \nindicated for persons being evaluated for hepatitis B protection \nbecause of occupational risk. Prevaccination serologic testing \nis indicated for all persons born in geographic regions with \nHBsAg prevalence of ≥2% (e.g., much of Eastern Europe, Asia,",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 30,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_31",
    "document_id": "rr6210",
    "text": "HBsAg prevalence of ≥2% (e.g., much of Eastern Europe, Asia, \nAfrica, the Middle East, and the Pacific Islands) and certain \nindigenous populations from countries with overall low HBV \nendemicity (<2%); persons with behavioral exposures to HBV \n(e.g., men who have sex with men and past or current injection \ndrug users); persons receiving cytotoxic or immunosuppressive \ntherapy; and persons with liver disease of unknown etiology.\n HBV endemicity (HBsAg prevalence) can be described as \nlow (<2%), moderate (2%–<8%), and high (≥8%). Because \ncertain persons might have been infected with HBV before they \nreceived HepB vaccination, HBsAg testing is recommended \nregardless of vaccination history for persons born in geographic \nregions with HBsAg prevalence of ≥2%, U.S.-born persons not",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 31,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_32",
    "document_id": "rr6210",
    "text": "regions with HBsAg prevalence of ≥2%, U.S.-born persons not \nvaccinated as infants whose parents were born in regions with \nhigh HBV endemicity (HBsAg prevalence) (≥8%), persons \nwho received HepB vaccination as adolescents or adults after \nthe initiation of risk behaviors (12), and persons who are \nHIV-positive or who receive hemodialysis (11).\nTesting HCP at risk for HBV infection should consist of a \nserologic assay for HBsAg, in addition to either anti-HBc or \nanti-HBs (11,12). For unvaccinated HCP at risk for previous \nHBV infection, blood should be drawn for testing before the \nfirst dose of vaccine is administered.\nVaccination\nAll HCP whose work-, training-, and volunteer-related \nactivities involve reasonably anticipated risk for exposure to",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 32,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_33",
    "document_id": "rr6210",
    "text": "activities involve reasonably anticipated risk for exposure to \nblood or body fluids should be vaccinated with a complete, \n≥3-dose HepB vaccine series. OSHA mandates that \nvaccination be available for employees within 10 days of \ninitial assignment (27). HCP trainees should complete the \nseries before the potential for exposure with blood or body \nfluids, when possible, as higher risk has been reported during \nprofessional training (e.g., residency training).\nIncompletely vaccinated HCP should receive additional \ndose(s) to complete the vaccine series (15). The vaccine series \ndoes not need to be restarted for HCP with an incomplete \nRecommendations and Reports\n12\t\nMMWR  /  December 20, 2013  /  Vol. 62  /  No. 10\nseries; however, minimum dosing intervals should be heeded",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 33,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_34",
    "document_id": "rr6210",
    "text": "series; however, minimum dosing intervals should be heeded \n(15). Minimum dosing intervals are 4 weeks between the first \nand second dose, 8 weeks between the second and third dose, \nand 16 weeks between the first and third dose (15).\nHCP lacking documentation of HepB vaccination should \nbe considered unvaccinated (when documentation for HepB \nvaccine doses is lacking) or incompletely vaccinated (when \ndocumentation for some HepB vaccine doses is lacking) and \nshould receive additional doses to complete a documented \nHepB series. Health-care institutions are encouraged to seek \ndocumentation of “missing” HepB doses in IIS, when feasible, \nto avoid unnecessary vaccination.\nOSHA mandates that HCP who refuse HepB vaccination \nsign a declination statement (http://www.osha.gov/pls/",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 34,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_35",
    "document_id": "rr6210",
    "text": "sign a declination statement (http://www.osha.gov/pls/\noshaweb/owadisp.show_document?p_id=10052&p_\ntable=STANDARDS). HCP refusing HepB vaccination can \nobtain vaccination at a later date at no expense if the HCP is \nstill covered under OSHA’s Bloodborne Pathogens Standard. \nHealth-care institutions should encourage HepB vaccination \namong HCP to improve HBV protection and to achieve the \nHealthy People 2020 target of 90% vaccination (66).\nPostvaccination Serologic Testing\nHCP who have written documentation of a complete, \n≥3-dose HepB vaccine series and subsequent postvaccination \nanti-HBs ≥10 mIU/mL are considered hepatitis B immune. \nImmunocompetent persons have long-term protection against \nHBV and do not need further periodic testing to assess \nanti-HBs levels (Figure 6).",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 35,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_36",
    "document_id": "rr6210",
    "text": "HBV and do not need further periodic testing to assess \nanti-HBs levels (Figure 6).\nAll HCP recently vaccinated or recently completing HepB \nvaccination who are at risk for occupational blood or body \nfluid exposure should undergo anti-HBs testing. Anti-HBs \ntesting should be performed 1–2 months after administration \nof the last dose of the vaccine series when possible. HCP with \ndocumentation of a complete ≥3-dose HepB vaccine series \nbut no documentation of anti-HBs ≥10 mIU/mL who are \nat risk for occupational blood or body fluid exposure might \nundergo anti-HBs testing upon hire or matriculation. Testing \nshould use a quantitative method that allows detection of \nthe protective concentration of anti-HBs (≥10 mIU/mL) \n(e.g., enzyme-linked immunosorbent assay [ELISA]).",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 36,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_37",
    "document_id": "rr6210",
    "text": "(e.g., enzyme-linked immunosorbent assay [ELISA]).\n• Completely vaccinated HCP with anti-HBs ≥10 mIU/mL \nare considered hepatitis B immune. Immunocompetent \npersons have long-term protection and do not need further \nperiodic testing to assess anti-HBs levels.\n• Completely vaccinated HCP with anti-HBs <10 mIU/mL \nshould receive an additional dose of HepB vaccine, followed \nby anti-HBs testing 1–2 months later. HCP whose \nanti-HBs remains <10 mIU/mL should receive 2 additional \nvaccine doses (usually 6 doses total), followed by repeat \nanti-HBs testing 1–2 months after the last dose. Alternatively, \nit might be more practical for very recently vaccinated HCP \nwith anti-HBs <10 mIU/mL to receive 3 consecutive \nadditional doses of HepB vaccine (usually 6 doses total),",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 37,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_38",
    "document_id": "rr6210",
    "text": "additional doses of HepB vaccine (usually 6 doses total), \nfollowed by anti-HBs testing 1–2 months after the last dose.\nStandard Precautions and Advising HCP to \nReport Exposures\nAll HCP should adhere to infection-control guidelines \nand follow Standard Precautions (90), including the use of \nengineering and work-practice controls, to reduce the risk \nfor blood or body fluid exposure. All HCP, including those \nwho have demonstrated protection against HBV, should be \nadvised to immediately report blood or body fluid exposures to \noccupational health for evaluation of the appropriate measures \nto prevent transmission of bloodborne pathogens (including \nHIV, hepatitis C, and hepatitis B).\nPostexposure Management\nInitial Postexposure Management",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 38,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_39",
    "document_id": "rr6210",
    "text": "HIV, hepatitis C, and hepatitis B).\nPostexposure Management\nInitial Postexposure Management\nWounds and skin sites that have been in contact with blood \nor body fluids should be washed with soap and water; mucous \nmembranes should be flushed with water. Using antiseptics \n(e.g., 2%–4% chlorhexidine) for wound care or expressing fluid \nby squeezing the wound further have not been shown to reduce \nthe risk for HBV transmission; however, the use of antiseptics \nis not contraindicated. The application of caustic agents \n(e.g., bleach) or the injection of antiseptics or disinfectants into \nthe wound is not recommended.\nProcedures should be followed for testing known source \npersons, including obtaining informed consent, in accordance \nwith applicable laws. Source patients determined to be",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 39,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_40",
    "document_id": "rr6210",
    "text": "with applicable laws. Source patients determined to be \nHBsAg-positive should be referred for appropriate management \nand should be reported to the state or local health department. \nWhen a source patient is unknown (e.g., as occurs from a \npuncture with a needle in the trash), the exposed HCP should \nbe managed as if the source patient were HBsAg-positive. \nTesting needles and other sharp instruments implicated in an \nexposure is not recommended, regardless of whether the source \npatient is known or unknown. The reliability and interpretation \nof findings in such circumstances are unknown, and testing \ncould be hazardous to persons handling the sharp instrument. \nExposures involving human bites should be managed with the \nknowledge that both the person being bitten and the person",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 40,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_41",
    "document_id": "rr6210",
    "text": "knowledge that both the person being bitten and the person \nwho engaged in biting were potentially exposed.\nInstitutions should ensure that HCP have timely access \nto postexposure management and prophylaxis, including \nRecommendations and Reports\nMMWR  /  December 20, 2013  /  Vol. 62  /  No. 10\t\n13\nThis figure provides guidance for pre-exposure evaluation \nof health\n-care pers\nonnel who\n have been\n complete\nly vaccina\nted with \n≥3 dose He\npB vaccine series and who have not\n had postvaccination serologic tes\nting.\nSource: Adapted from CDC. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations \nof the Advisory Committee on Immunization Practices (ACIP). Part II: immunization of adults. MMWR 2006;55(No. RR-16).",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 41,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_42",
    "document_id": "rr6210",
    "text": "*\tShould be performed 1–2 months after the last dose of vaccine using a quantitative method that allows detection of the protective concentration of anti-HBs \n(≥10 mIU/mL) (e.g., enzyme-linked immunosorbent assay [ELISA]).\n†\tA nonresponder is defined as a person with anti-HBs <10 mIU/mL after ≥6 doses of HepB vaccine. Persons who do not have a protective concentration of anti-HBs \nafter revaccination should be tested for HBsAg. If positive, the person should receive appropriate management or vaccination.\nFIGURE 6. Pre-exposure evaluation for health-care personnel previously vaccinated with complete, ≥3-dose HepB vaccine series who have \nnot had postvaccination serologic testing* \nRecommendations and Reports\n14\t\nMMWR  /  December 20, 2013  /  Vol. 62  /  No. 10",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 42,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_43",
    "document_id": "rr6210",
    "text": "Recommendations and Reports\n14\t\nMMWR  /  December 20, 2013  /  Vol. 62  /  No. 10\nHBIG and HepB vaccine. For exposed HCP thought to \nbe susceptible to HBV infection, HBIG and HepB vaccine \nshould be administered as soon as possible after an exposure \nwhen indicated. The effectiveness of HBIG when administered \n>7 days after percutaneous, mucosal, or nonintact skin \nexposures is unknown. HBIG and HepB vaccine can be \nadministered simultaneously at separate injection sites.\nAnti-HBs testing of HCP who received HBIG should be \nperformed after anti-HBs from HBIG is no longer detectable \n(6 months after administration) (11). Anti-HBs testing should \nbe performed using a method that allows detection of the \nprotective concentration of anti-HBs (≥10 mIU/mL) (Table 2).\nManaging Vaccinated HCP",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 43,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_44",
    "document_id": "rr6210",
    "text": "protective concentration of anti-HBs (≥10 mIU/mL) (Table 2).\nManaging Vaccinated HCP\nFor vaccinated HCP (who have written documentation of \na complete, ≥3-dose HepB vaccine series) with subsequent \ndocumented anti-HBs ≥10 mIU/mL, testing the source patient \nfor HBsAg is unnecessary. No postexposure management \nfor HBV is necessary, regardless of the source patient’s \nHBsAg status.\nFor vaccinated HCP (who have written documentation of \nHepB vaccination) with anti-HBs <10 mIU/mL after two \ncomplete, ≥3-dose HepB vaccine series, the source patient \nshould be tested for HBsAg as soon as possible after the \nexposure. If the source patient is HBsAg-positive or has \nunknown HBsAg status, the HCP should receive 2 doses \nof HBIG (1,11). The first dose should be administered as",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 44,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_45",
    "document_id": "rr6210",
    "text": "of HBIG (1,11). The first dose should be administered as \nsoon as possible after the exposure, and the second dose \nshould be administered 1 month later. If the source patient is \nHBsAg-negative, neither HBIG nor HepB vaccine is necessary.\nFor vaccinated HCP (who have written documentation of \na complete, ≥3-dose HepB vaccine series) without previous \nanti-HBs testing, the HCP should be tested for anti-HBs and \nthe source patient (if known) should be tested for HBsAg as \nsoon as possible after the exposure. Testing the source patient \nand the HCP should occur simultaneously; testing the source \npatient should not be delayed while waiting for the HCP \nanti-HBs test results, and likewise, testing the HCP should not \nbe delayed while waiting for the source patient HBsAg results.",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 45,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_46",
    "document_id": "rr6210",
    "text": "be delayed while waiting for the source patient HBsAg results.\nTABLE 2. Postexposure management of health-care personnel after occupational percutaneous and mucosal exposure to blood and body \nfluids, by health-care personnel HepB vaccination and response status\nHealth-care personnel status\nPostexposure testing\nPostexposure prophylaxis\nPostvaccination \nserologic \ntesting†\nSource patient\n(HBsAg)\nHCP testing\n(anti-HBs)\nHBIG*\nVaccination\nDocumented responder§ after \ncomplete series (≥3 doses)\nNo action needed\nDocumented nonresponder¶ \nafter 6 doses\nPositive/unknown\n—**\nHBIG x2 separated \nby 1 month\n—\nNo\nNegative\nNo action needed\nResponse unknown after \n3 doses\nPositive/unknown\n<10mIU/mL**\nHBIG x1\nInitiate \nrevaccination\nYes\nNegative\n<10mIU/mL\nNone\nAny result\n≥10mIU/mL\nNo action needed",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 46,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_47",
    "document_id": "rr6210",
    "text": "HBIG x1\nInitiate \nrevaccination\nYes\nNegative\n<10mIU/mL\nNone\nAny result\n≥10mIU/mL\nNo action needed\nUnvaccinated/incompletely \nvaccinated or vaccine refusers\nPositive/unknown\n—**\nHBIG x1\nComplete \nvaccination\nYes\nNegative\n—\nNone\nComplete \nvaccination\nYes\nAbbreviations: HCP = health-care personnel; HBsAg = hepatitis B surface antigen; anti-HBs = antibody to hepatitis B surface antigen; HBIG = hepatitis B immune globulin.\n\t *\tHBIG should be administered intramuscularly as soon as possible after exposure when indicated. The effectiveness of HBIG when administered >7 days after \npercutaneous, mucosal, or nonintact skin exposures is unknown. HBIG dosage is 0.06 mL/kg.",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 47,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_48",
    "document_id": "rr6210",
    "text": "percutaneous, mucosal, or nonintact skin exposures is unknown. HBIG dosage is 0.06 mL/kg.\n\t †\tShould be performed 1–2 months after the last dose of the HepB vaccine series (and 4–6 months after administration of HBIG to avoid detection of passively \nadministered anti-HBs) using a quantitative method that allows detection of the protective concentration of anti-HBs (≥10 mIU/mL). \n\t §\tA responder is defined as a person with anti-HBs ≥10 mIU/mL after ≥3 doses of HepB vaccine.\n\t ¶\tA nonresponder is defined as a person with anti-HBs <10 mIU/mL after ≥6 doses of HepB vaccine.\n\t**\tHCP who have anti-HBs <10mIU/mL, or who are unvaccinated or incompletely vaccinated, and sustain an exposure to a source patient who is HBsAg-positive or",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 48,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_49",
    "document_id": "rr6210",
    "text": "has unknown HBsAg status, should undergo baseline testing for HBV infection as soon as possible after exposure, and follow-up testing approximately 6 months \nlater. Initial baseline tests consist of total anti-HBc; testing at approximately 6 months consists of HBsAg and total anti-HBc.\nRecommendations and Reports\nMMWR  /  December 20, 2013  /  Vol. 62  /  No. 10\t\n15\n• If the HCP has anti-HBs <10 mIU/mL and the source \npatient is HBsAg-positive or has unknown HBsAg status, \nthe HCP should receive 1 dose of HBIG and be revaccinated \nas soon as possible after the exposure. The HCP should \nthen receive the second 2 doses to complete the second \nHepB vaccine series (6 doses total when accounting for the \noriginal 3-dose series) according to the vaccination",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 49,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_50",
    "document_id": "rr6210",
    "text": "original 3-dose series) according to the vaccination \nschedule. To document the HCP’s vaccine response status \nfor future exposures, anti-HBs testing should be performed \n1–2 months after the last dose of vaccine.\n• If the HCP has anti-HBs <10 mIU/mL and the source \npatient is HBsAg-negative, the HCP should receive an \nadditional HepB vaccine dose, followed by repeat anti-HBs \ntesting 1–2 months later. HCP whose anti-HBs remains \n<10 mIU/mL should undergo revaccination with 2 more \ndoses (6 doses total when accounting for the original 3-dose \nseries). To document the HCP’s vaccine response status for \nfuture exposures, anti-HBs testing should be performed \n1–2 months after the last dose of vaccine.\n• If the HCP has anti-HBs ≥10 mIU/mL at the time of the",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 50,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_51",
    "document_id": "rr6210",
    "text": "1–2 months after the last dose of vaccine.\n• If the HCP has anti-HBs ≥10 mIU/mL at the time of the \nexposure, no postexposure HBV management is necessary, \nregardless of the source patient’s HBsAg status.\nManaging HCP Who Lack Documentation of \nVaccination, are Unvaccinated or \nIncompletely Vaccinated\nFor unvaccinated or incompletely vaccinated HCP (including \nthose who refused vaccination), the source patient should be \ntested for HBsAg as soon as possible after the exposure. Testing \nunvaccinated or incompletely vaccinated HCP for anti-HBs is \nnot necessary and is potentially misleading, because anti-HBs \n≥10 mIU/mL as a correlate of vaccine-induced protection has \nonly been determined for persons who have completed an \napproved vaccination series (15,42).",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 51,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_52",
    "document_id": "rr6210",
    "text": "only been determined for persons who have completed an \napproved vaccination series (15,42).\n• If the source patient is HBsAg-positive or has unknown \nHBsAg status, the HCP should receive 1 dose of HBIG \nand 1 dose of HepB vaccine administered as soon as \npossible after the exposure. The HCP should complete \nthe HepB vaccine series according to the vaccination \nschedule. To document the HCP’s vaccine response status \nfor future exposures, anti-HBs testing should be performed \napproximately 1–2 months after the last dose of vaccine. \nBecause anti-HBs testing of HCP who received HBIG \nshould be performed after anti-HBs from HBIG is no \nlonger detectable (6 months after administration), it will \nlikely be necessary to defer anti-HBs testing for a period",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 52,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_53",
    "document_id": "rr6210",
    "text": "likely be necessary to defer anti-HBs testing for a period \nlonger than 1–2 months after the last vaccine dose.\n–– HCP with anti-HBs ≥10 mIU/mL after receipt of the \nprimary vaccine series are considered immune. \nImmunocompetent persons have long-term protection \nand do not need further periodic testing to assess anti-\nHBs levels.\n–– HCP with anti-HBs <10 mIU/mL after receipt of the \nprimary series should be revaccinated. For these HCP, \nadministration of a second complete 3-dose series on an \nappropriate schedule, followed by anti-HBs testing \n1–2 months after the third dose, usually is more practical \nthan conducting serologic testing after each additional \ndose of vaccine. To document the HCP’s vaccine response \nstatus for future exposures, anti-HBs testing should be",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 53,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_54",
    "document_id": "rr6210",
    "text": "status for future exposures, anti-HBs testing should be \nperformed 1–2 months after the last dose of vaccine.\n• If the source patient is HBsAg-negative, the HCP should \ncomplete the HepB vaccine series according to the \nvaccination schedule. To document the HCP’s vaccine \nresponse status for future exposures, anti-HBs testing \nshould be performed approximately 1–2 months after the \nlast dose of vaccine.\n–– HCP with anti-HBs ≥10 mIU/mL after receipt of the \nprimary vaccine series are considered immune. \nImmunocompetent persons have long-term protection \nand do not need further periodic testing to assess anti-\nHBs levels.\n–– HCP with anti-HBs <10 mIU/mL after receipt of the \nprimary series should be revaccinated. For these HCP, \nadministration of a second complete 3-dose series on",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 54,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_55",
    "document_id": "rr6210",
    "text": "administration of a second complete 3-dose series on \nan appropriate schedule, followed by anti-HBs testing \n1–2 months after the third dose, usually is more \npractical than conducting serologic testing after each \nadditional dose of vaccine. To document the HCP’s \nvaccine response status for future exposures, anti-HBs \ntesting should be performed 1–2 months after the last \ndose of vaccine.\nTesting of HCP Exposed to an HBsAg-Positive or \nUnknown Source\nHCP who have anti-HBs <10 mIU/mL, or who are \nunvaccinated or incompletely vaccinated, and who sustain a \npercutaneous, mucosal, or nonintact skin exposure to a source \npatient who is HBsAg-positive or has unknown HBsAg status \nshould undergo baseline testing for HBV infection as soon as",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 55,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_56",
    "document_id": "rr6210",
    "text": "should undergo baseline testing for HBV infection as soon as \npossible after the exposure, and follow-up testing approximately \n6 months later. Testing immediately after the exposure should \nconsist of total anti-HBc, and follow-up testing approximately \n6 months later should consist of HBsAg and total anti-HBc.\nHCP exposed to a source patient who is HBsAg-positive \nor has unknown HBsAg status do not need to take special \nprecautions to prevent secondary transmission during the \nfollow-up period; however, they should refrain from donating \nblood, plasma, organs, tissue, or semen (1). The exposed \nHCP does not need to modify sexual practices or refrain from \nRecommendations and Reports\n16\t\nMMWR  /  December 20, 2013  /  Vol. 62  /  No. 10",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 56,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_57",
    "document_id": "rr6210",
    "text": "Recommendations and Reports\n16\t\nMMWR  /  December 20, 2013  /  Vol. 62  /  No. 10\nbecoming pregnant (1). If an exposed HCP is breast feeding, \nshe does not need to discontinue (1). No modifications to \nan exposed HCP’s patient-care responsibilities are necessary \nto prevent transmission to patients based solely on exposure \nto a source patient who is HBsAg-positive or has unknown \nHBsAg status.\nVaccine Nonresponders\nVaccinated HCP whose anti-HBs remains <10 mIU/mL after \nrevaccination (i.e., after receiving a total of 6 doses) should \nbe tested for HBsAg and anti-HBc to determine infection \nstatus. Those determined not to be HBV infected (vaccine \nnonresponders) should be considered susceptible to HBV \ninfection. No specific work restrictions are recommended for",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 57,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_58",
    "document_id": "rr6210",
    "text": "infection. No specific work restrictions are recommended for \nvaccine nonresponders (91).\nDocumentation\nHealth-care institutions should maintain records, ideally \nelectronic records that are easily retrievable following exposures, \nof documented vaccination histories and serologic test results for \nreference in managing occupational exposures, and to provide \nto other health-care institutions if requested by the HCP. The \nvaccination information should be entered into an IIS accepting \nrecords from adult vaccination, if available. HCP should be \nprovided a copy of HepB vaccination and anti-HBs testing \nresults and encouraged to keep them with their personal health \nrecords so they can readily be made available to future employers.\nHCP with HBV Infection",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 58,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_59",
    "document_id": "rr6210",
    "text": "records so they can readily be made available to future employers.\nHCP with HBV Infection\nHCP who are positive for HBsAg should be counseled \nhow to prevent HBV transmission to others and referred for \nfurther evaluation (92). Those who perform exposure-prone \nprocedures should be advised regarding the procedures they \ncan perform safely as per updated CDC recommendations \nfor the management of HBsAg-positive health-care providers \nand students (11,13). Chronic hepatitis B infection in itself \nshould not preclude the practice or study of medicine, surgery, \ndentistry, or allied health professions (13).\nFuture Studies\nNational surveillance systems to accurately assess the burden \nof hepatitis B among HCP and health-care facility databases",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 59,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_60",
    "document_id": "rr6210",
    "text": "of hepatitis B among HCP and health-care facility databases \ntracking occupational exposures among HCP are important for \nmonitoring the changing epidemiology of occupationally acquired \nHBV infections and other bloodborne pathogens. Systems and \ndatabases could ideally be electronically linked to employee \nhealth records and should include results that identify HepB \nvaccine responders and nonresponders, the nature and HBV \nstatus of the exposure source and postexposure management, \nand the HCP’s anti-HBs level. Appropriate safeguards should be \nin place to protect the privacy of the health information. Data \ncollection should be representative of HCP in a variety of settings \n(e.g., acute care, long-term care, and dialysis), including settings",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 60,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_61",
    "document_id": "rr6210",
    "text": "(e.g., acute care, long-term care, and dialysis), including settings \nwith frequent staff turnover. Studies assessing HBV transmission \namong all HCP exposed to an HBsAg-positive source, regardless \nof vaccination history or anti-HBs levels, approximately \n6 months after an exposure will help to inform duration of \nvaccine protection. Surveillance activities for acute hepatitis B \ninfection should continue to ascertain occupation among cases, \nin addition to HepB vaccination history. Long-term follow-up \nstudies assessing disease incidence and duration of anti-HBs \namong persons vaccinated as infants and older adults, including \npersons who received booster doses subsequent to the primary \nvaccine series and persons from HBV-endemic areas, also might",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 61,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_62",
    "document_id": "rr6210",
    "text": "vaccine series and persons from HBV-endemic areas, also might \nprovide information on duration of vaccine-induced protection. \nOther subject areas that would benefit from research include \nefficacy and cost-effectiveness of antiviral agents for postexposure \nprophylaxis, immunogenicity of higher dosage or new vaccines \nfor revaccinating vaccine nonresponders, and an examination of \nthe future role of postexposure hepatitis B virus deoxyribonucleic \nacid (HBV DNA) testing.\nAcknowledgments\nThe following persons were consulted during the drafting of \nthese recommendations: Thomas J. Hoerger, PhD, Christina \nLudlow-Bradley, Research Triangle Institute, International, Durham, \nNorth Carolina; Henry Roberts, PhD, Emily Smith, MPH, Steven",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 62,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_63",
    "document_id": "rr6210",
    "text": "North Carolina; Henry Roberts, PhD, Emily Smith, MPH, Steven \nVeselsky, MPH, National Center for HIV/AIDS, Viral Hepatitis, \nSTD, and TB Prevention; Donna Weaver, RN, National Center for \nImmunization and Respiratory Diseases; Tara MacCannell, PhD, \nRonda Sinkowitz-Cochran, MPH, National Center for Emerging \nand Zoonotic Infectious Diseases.\nReferences\n\t 1.\tUS Public Health Service. Updated U.S. Public Health Service guidelines \nfor the management of occupational exposures to HBV, HCV, and HIV \nand recommendations for postexposure prophylaxis. MMWR \n2001;29:50(No. RR-11).\n\t 2.\tRosenberg JL, Jones DP, Lipitz LR, Kirsner JB. Viral hepatitis: an \noccupational hazard to surgeons. JAMA 1973;223:395–400. \n\t 3.\tTrinkoff AM, Le R, Geiger-Brown J, Lipscomb J. Work schedule, needle",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 63,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_64",
    "document_id": "rr6210",
    "text": "3.\tTrinkoff AM, Le R, Geiger-Brown J, Lipscomb J. Work schedule, needle \nuse, and needlestick injuries among registered nurses. Infect Control \nHosp Epidemiol 2007;28:156–64. \n\t 4.\tBeltrami EM, Williams IT, Shapiro CN, Chamberland ME. Risk and \nmanagement of blood-borne infections in health care workers. Clin \nMicrobiol Rev 2000;13:385–407. \n\t 5.\tCDC. Recommendation of the Immunization Practices Advisory \nCommittee (ACIP). Inactivated hepatitis B virus vaccine. MMWR \n1982;31:317–22, 27–8.\n\t 6.\tAverhoff F, Mahoney F, Coleman P, et al. Immunogenicity of hepatitis B \nvaccines. Implications for persons at occupational risk of hepatitis B \nvirus infection. Am J Prev Med 1998;15:1–8. \n\t 7.\tHadler SC, Francis DP, Maynard JE, et al. Long-term immunogenicity",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 64,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_65",
    "document_id": "rr6210",
    "text": "7.\tHadler SC, Francis DP, Maynard JE, et al. Long-term immunogenicity \nand efficacy of hepatitis B vaccine in homosexual men. N Engl J Med \n1986;315:209–14. \nRecommendations and Reports\nMMWR  /  December 20, 2013  /  Vol. 62  /  No. 10\t\n17\n\t 8.\tCDC. Update on adult immunization: recommendations of the \nAdvisory Committee on Immunization Practices (ACIP). MMWR 1991;​\n40(No. RR-12).\n\t 9.\tCDC. Immunization of health-care workers: recommendations of the \nAdvisory Committee on Immunization Practices (ACIP) and the \nHospital Infection Control Practices Advisory Committee (HICPAC). \nMMWR 1997;46(No. RR-18).\n\t10.\tCDC. Viral hepatitis statistics and surveillance. Available at http://\nwww.cdc.gov/hepatitis/statistics/index.htm.",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 65,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_66",
    "document_id": "rr6210",
    "text": "www.cdc.gov/hepatitis/statistics/index.htm.\n\t11.\tCDC. Immunization of health-care personnel: recommendations of the \nAdvisory Committee on Immunization Practices (ACIP). MMWR \n2011;60(No. RR-7).\n\t12.\tCDC. Recommendations for identification and public health management \nof persons with chronic hepatitis B virus infection. MMWR 2008;​\n57(No. RR-8).\n\t13.\tCDC. Updated CDC recommendations for the management of \nhepatitis B virus-infected health-care providers and students. MMWR \n2012;61(No. RR-3).\n\t14.\tCDC. Updated US Public Health Service guidelines for the management \nof occupational exposures to HIV and recommendations for postexposure \nprophylaxis. MMWR 2005;54(No. RR-9).\n\t15. CDC. A comprehensive immunization strategy to eliminate transmission",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 66,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_67",
    "document_id": "rr6210",
    "text": "15. CDC. A comprehensive immunization strategy to eliminate transmission \nof hepatitis B virus infection in the United States: recommendations of \nthe Advisory Committee on Immunization Practices (ACIP) part II: \nimmunization of adults. MMWR 2006;55(No. RR-16); quiz.\n\t16.\tCDC. Hepatitis B virus: a comprehensive strategy for eliminating \ntransmission in the United States through universal childhood vaccination: \nrecommendations of the Advisory Committee on Immunization Practices \n(ACIP). MMWR 1991;40(No. RR-13).\n\t17.\tCDC. 2012 Case definitions: Nationally notifiable conditions infectious \nand non-infectious cases. Atlanta, GA: CDC; 2012.\n\t18.\tHyams KC. Risks of chronicity following acute hepatitis B virus \ninfection: a review. Clin Infect Dis 1995;20:992–1000.",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 67,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_68",
    "document_id": "rr6210",
    "text": "infection: a review. Clin Infect Dis 1995;20:992–1000. \n\t19.\tWasley A, Kruszon-Moran D, Kuhnert W, et al. The prevalence of \nhepatitis B virus infection in the United States in the era of vaccination. \nJ Infect Dis 2010;202:192–201. \n\t20.\tLy KN, Xing J, Klevens RM, et al. The increasing burden of mortality \nfrom viral hepatitis in the United States between 1999 and 2007. Ann \nIntern Med 2012;156:271–8. \n\t21.\tCDC. National, state, and local area vaccination coverage among children \naged 19–35 months—United States, 2011. MMWR 2012;61:689–96.\n\t22.\tCDC. National and state vaccination coverage among adolescents aged \n13–17 years—United States, 2011. MMWR 2012;61:671–7.\n\t23.\tCDC. Noninfluenza vaccination coverage among adults—United States, \n2011. MMWR 2013;62:66–72.",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 68,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_69",
    "document_id": "rr6210",
    "text": "23.\tCDC. Noninfluenza vaccination coverage among adults—United States, \n2011. MMWR 2013;62:66–72.\n\t24.\tBond WW, Favero MS, Petersen NJ, et al. Survival of hepatitis B virus \nafter drying and storage for one week. Lancet 1981;1:550–1. \n\t25.\tGaribaldi RA, Hatch FE, Bisno AL, Hatch MH, Gregg MB. Nonparenteral \nserum hepatitis: report of an outbreak. JAMA 1972;220:963–6. \n\t26.\tWerner BG, Grady GF. Accidental hepatitis-B-surface-antigen-positive \ninoculations: use of e antigen to estimate infectivity. Ann Intern Med \n1982;97:367–9. \n\t27.\tUS Department of Labor. Occupational Health and Safety Administration. \nAvailable at http://www.osha.gov.\n\t28.\tUniversity of Virginia Health System. International healthcare worker \nsafety center. Available at http://www.healthsystem.virginia.edu/pub/",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 69,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_70",
    "document_id": "rr6210",
    "text": "safety center. Available at http://www.healthsystem.virginia.edu/pub/\nepinet/home.html.\n\t29.\tBoal WL, Leiss JK, Sousa S, et al. The national study to prevent blood \nexposure in paramedics: exposure reporting. Am J Ind Med 2008;51:213–22. \n\t30.\tGershon RR, Pearson JM, Sherman MF, et al. The prevalence and risk \nfactors for percutaneous injuries in registered nurses in the home health \ncare sector. Am J Infect Control 2009;37:525–33. \n\t31.\tGershon RR, Qureshi KA, Pogorzelska M, et al. Non-hospital based \nregistered nurses and the risk of bloodborne pathogen exposure. Ind \nHealth 2007;45:695–704. \n\t32.\tLipscomb J, Sokas R, McPhaul K, et al. Occupational blood exposure \namong unlicensed home care workers and home care registered nurses: \nare they protected? Am J Ind Med 2009;52:563–70.",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 70,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_71",
    "document_id": "rr6210",
    "text": "are they protected? Am J Ind Med 2009;52:563–70. \n\t33.\tDement JM, Epling C, Ostbye T, Pompeii LA, Hunt DL. Blood and \nbody fluid exposure risks among health care workers: results from the \nDuke Health and Safety Surveillance System. Am J Ind Med 2004;​\n46:637–48. \n\t34.\tCDC. 2000–2012 exposure logs at three healthcare systems in the United \nStates. Personal Communication, Sarah Schillie.\n\t35.\tWang S, editor. Hepatitis B collaborative care model: implementation at \na community health center. Healthfirst 2011 fall symposium integrating \nhealthcare: planning and systems to improve health outcomes; 2011.\n\t36.\tHadler SC, Margolis HS. Hepatitis B immunization: vaccine types, \nefficacy, and indications for immunization. Curr Clin Top Infect Dis \n1992;12:282–308.",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 71,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_72",
    "document_id": "rr6210",
    "text": "efficacy, and indications for immunization. Curr Clin Top Infect Dis \n1992;12:282–308.\n\t37.\tStratton K, Ford A, Rusch E, Clayton EW. Adverse effects of vaccines: \nevidence and causality. Washington, DC: The National Academies \nPress; 2012.\n\t38.\tAyoola EA, Johnson AO. Hepatitis B vaccine in pregnancy: immunogenicity, \nsafety and transfer of antibodies to infants. Int J Gynaecol Obstet 1987;​\n25:297–301. \n\t39.\tLevy M, Koren G. Hepatitis B vaccine in pregnancy: maternal and fetal \nsafety. Am J Perinatol 1991;8:227–32. \n\t40.\tLeuridan E, Van Damme P. Hepatitis B and the need for a booster dose. \nClin Infect Dis 2011;53:68–75. \n\t41.\tMcMahon BJ, Dentinger CM, Bruden D, et al. Antibody levels and \nprotection after hepatitis B vaccine: results of a 22-year follow-up study",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 72,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_73",
    "document_id": "rr6210",
    "text": "protection after hepatitis B vaccine: results of a 22-year follow-up study \nand response to a booster dose. J Infect Dis 2009;200:1390–6.\n\t42.\tJack AD, Hall AJ, Maine N, Mendy M, Whittle HC. What level of \nhepatitis B antibody is protective? J Infect Dis 1999;179:489–92. \n\t43.\tAlikaşifoğlu M, Cullu F, Kutlu T, et al. Comparison study of the \nimmunogenicity of different types and dosages of recombinant \nhepatitis B vaccine in healthy neonates. J Trop Pediatr 2001;47:60–2.\n\t44.\tGoldfarb J, Baley J, Medendorp SV, et al. Comparative study of the \nimmunogenicity and safety of two dosing schedules of Engerix-B \nhepatitis B vaccine in neonates. Pediatr Infect Dis J 1994;13:18–21. \n\t45.\tSchillie SF, Murphy TV. Seroprotection after recombinant hepatitis B",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 73,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_74",
    "document_id": "rr6210",
    "text": "45.\tSchillie SF, Murphy TV. Seroprotection after recombinant hepatitis B \nvaccination among newborn infants: a review. Vaccine 2013;31:2506–16. \n\t46.\tBouter KP, Diepersloot RJ, Wismans PJ, et al. Humoral immune response \nto a yeast-derived hepatitis B vaccine in patients with type 1 diabetes \nmellitus. Diabet Med 1992;9:66–9. \n\t47.\tWeber DJ, Rutala WA, Samsa GP, Santimaw JE, Lemon SM. Obesity \nas a predictor of poor antibody response to hepatitis B plasma vaccine. \nJAMA 1985;254:3187–9. \n\t48.\tWood RC, MacDonald KL, White KE, et al. Risk factors for lack of \ndetectable antibody following hepatitis B vaccination of Minnesota \nhealth care workers. JAMA 1993;270:2935–9. \n\t49.\tDentinger CM, McMahon BJ, Butler JC, et al. Persistence of antibody",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 74,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_75",
    "document_id": "rr6210",
    "text": "49.\tDentinger CM, McMahon BJ, Butler JC, et al. Persistence of antibody \nto hepatitis B and protection from disease among Alaska natives \nimmunized at birth. Pediatr Infect Dis J 2005;24:786–92. \n\t50.\tHammitt LL, Hennessy TW, Fiore AE, et al. Hepatitis B immunity in \nchildren vaccinated with recombinant hepatitis B vaccine beginning at \nbirth: a follow-up study at 15 years. Vaccine 2007;25:6958–64. \n\t51.\tMiddleman AB, Baker C, Hu DJ, et al. Duration of immunity from \nhepatitis B vaccine administered soon after birth among 16 to 19 year \nold youth in the United States. Presented to the Pediatric Academic \nSocieties, Boston, MA, April 29, 2012.\n\t52.\tPetersen KM, Bulkow LR, McMahon BJ, et al. Duration of hepatitis B \nimmunity in low risk children receiving hepatitis B vaccinations from",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 75,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_76",
    "document_id": "rr6210",
    "text": "immunity in low risk children receiving hepatitis B vaccinations from \nbirth. Pediatr Infect Dis J 2004;23:650–5. \n\t53.\tSamandari T, Fiore AE, Negus S, et al. Differences in response to a \nhepatitis B vaccine booster dose among Alaskan children and adolescents \nvaccinated during infancy. Pediatrics 2007;120:e373–81. \nRecommendations and Reports\n18\t\nMMWR  /  December 20, 2013  /  Vol. 62  /  No. 10\n\t54.\tAdvisory Committee on Immunization Practices. Reilly M. Evidence \nfor cost-effectiveness analysis: non-cost related model inputs. Atlanta, \nGeorgia: CDC; 2012. Available at http://www.cdc.gov/vaccines/acip/\nmeetings/downloads/min-archive/min-jun12.pdf. \n\t55.\tFunderburke PL, Spencer L. Hepatitis B immunity in high risk health",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 76,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_77",
    "document_id": "rr6210",
    "text": "55.\tFunderburke PL, Spencer L. Hepatitis B immunity in high risk health \ncare workers. Seven years post vaccination. AAOHN J 2000;48:325–30.\n\t56.\tMcMahon B, editor. 30 year follow-up after Hepatitis B vaccination in \nadults and children. Technical Viral Hepatitis Prevention Board meeting; \nMilan, Italy; 2011.\n\t57.\tMcMahon BJ, Bruden DL, Petersen KM, et al. Antibody levels and \nprotection after hepatitis B vaccination: results of a 15-year follow-up. \nAnn Intern Med 2005;142:333–41. \n\t58.\tSpradling PR, Williams RE, Xing J, Soyemi K, Towers J. Serologic testing \nfor protection against hepatitis B virus infection among students at a \nhealth sciences university in the United States. Infect Control Hosp \nEpidemiol 2012;33:732–6.",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 77,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_78",
    "document_id": "rr6210",
    "text": "health sciences university in the United States. Infect Control Hosp \nEpidemiol 2012;33:732–6. \n\t59.\tStevens CE, Toy PT, Taylor PE, Lee T, Yip HY. Prospects for control of \nhepatitis B virus infection: implications of childhood vaccination and \nlong-term protection. Pediatrics 1992;90:170–3.\n\t60.\tTohme RA, Ribner B, Huey MJ, Spradling PR. Hepatitis B vaccination \ncoverage and documented seroprotection among matriculating healthcare \nstudents at an academic institution in the United States. Infect Control \nHosp Epidemiol 2011;32:818–21. \n\t61.\tWatson B, West DJ, Chilkatowsky A, Piercy S, Ioli VA. Persistence of \nimmunologic memory for 13 years in recipients of a recombinant \nhepatitis B vaccine. Vaccine 2001;19:3164–8. \n\t62.\tWilliams JL, Christensen CJ, McMahon BJ, et al. Evaluation of the",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 78,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_79",
    "document_id": "rr6210",
    "text": "62.\tWilliams JL, Christensen CJ, McMahon BJ, et al. Evaluation of the \nresponse to a booster dose of hepatitis B vaccine in previously immunized \nhealthcare workers. Vaccine 2001;19:4081–5. \n\t63.\tPoovorawan Y, Chongsrisawat V, Theamboonlers A, et al. Evidence of \nprotection against clinical and chronic hepatitis B infection 20 years \nafter infant vaccination in a high endemicity region. J Viral Hepat 2011;​\n18:369–75. \n\t64.\tZhu CL, Liu P, Chen T, et al. Presence of immune memory and immunity \nto hepatitis B virus in adults after neonatal hepatitis B vaccination. Vaccine \n2011;29:7835–41. \n\t65.\tByrd KB, Lu PJ, Murphy TV. Hepatitis B vaccination coverage among health-\ncare personnel in the United States. Public Health Rep 2013;128:498–509.",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 79,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_80",
    "document_id": "rr6210",
    "text": "care personnel in the United States. Public Health Rep 2013;128:498–509.\n\t66.\tCDC. Healthy people topics and objectives index. Available at http://\nwww.healthypeople.gov/2020/topicsobjectives2020/default.aspx.\n\t67.\tCDC. Harriman K. Survey administered to infection preventionists in \nCalifornia healthcare institutions. Atlanta, GA: CDC; 2012.\n\t68.\tClemens R, Sanger R, Kruppenbacher J, et al. Booster immunization of \nlow- and non-responders after a standard three dose hepatitis B vaccine \nschedule–results of a post-marketing surveillance. Vaccine 1997;15:349–52. \n\t69.\tCraven DE, Awdeh ZL, Kunches LM, et al. Nonresponsiveness to \nhepatitis B vaccine in health care workers. Results of revaccination and \ngenetic typings. Ann Intern Med 1986;105:356–60.",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 80,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_81",
    "document_id": "rr6210",
    "text": "genetic typings. Ann Intern Med 1986;105:356–60. \n\t70.\tBertino JS Jr, Tirrell P, Greenberg RN, et al. A comparative trial of standard \nor high-dose S subunit recombinant hepatitis B vaccine versus a vaccine \ncontaining S subunit, pre-S1, and pre-S2 particles for revaccination of \nhealthy adult nonresponders. J Infect Dis 1997;175:678–81. \n\t71.\tGoldwater PN. Randomized, comparative trial of 20 micrograms vs \n40 micrograms Engerix B vaccine in hepatitis B vaccine non-responders. \nVaccine 1997;15:353–6. \n\t72.\tAlter MJ, Hadler SC, Margolis HS, et al. The changing epidemiology \nof hepatitis B in the United States: need for alternative vaccination \nstrategies. JAMA 1990;263:1218–22. \n\t73.\tOsterholm MT, Garayalde SM. Clinical viral hepatitis B among",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 81,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_82",
    "document_id": "rr6210",
    "text": "73.\tOsterholm MT, Garayalde SM. Clinical viral hepatitis B among \nMinnesota hospital personnel: results of a ten-year statewide survey. \nJAMA 1985;254:3207–12. \n\t74.\tTosti ME, editor. Breakthrough HBV infections in vaccinated people: \na ten-year surveillance study in Italy. Technical Viral Hepatitis Prevention \nBoard meeting. Milan, Italy; 2011.\n\t75.\tCDC. Assessment of Hepatitis B vaccination history among healthcare \npersonnel with acute Hepatitis B. CDC Surveillance Project; 2012.\n\t76.\tCDC. Immunization Information Systems. Available at http://www.cdc.gov/\nvaccines/programs/iis/index.html.\n\t77.\tCDC. Immunization Information Systems. Personal communication, \nGary Urquhart; 2012.\n\t78.\tShi Z, Li X, Ma L, Yang Y. Hepatitis B immunoglobulin injection in",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 82,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_83",
    "document_id": "rr6210",
    "text": "Gary Urquhart; 2012.\n\t78.\tShi Z, Li X, Ma L, Yang Y. Hepatitis B immunoglobulin injection in \npregnancy to interrupt hepatitis B virus mother-to-child transmission-a \nmeta-analysis. Int J Infect Dis 2010;14:e622–34. \n\t79.\tBeasley RP, Hwang LY, Lee GC, et al. Prevention of perinatally \ntransmitted hepatitis B virus infections with hepatitis B virus infections \nwith hepatitis B immune globulin and hepatitis B vaccine. Lancet \n1983;2:1099–102. \n\t80.\tStevens CE, Toy PT, Tong MJ, et al. Perinatal hepatitis B virus transmission \nin the United States: prevention by passive-active immunization. JAMA \n1985;253:1740–5. \n\t81.\tBeasley RP, Hwang LY, Stevens CE, et al. Efficacy of hepatitis B immune \nglobulin for prevention of perinatal transmission of the hepatitis B virus",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 83,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_84",
    "document_id": "rr6210",
    "text": "globulin for prevention of perinatal transmission of the hepatitis B virus \ncarrier state: final report of a randomized double-blind, placebo-\ncontrolled trial. Hepatology 1983;3:135–41. \n\t82.\tGrady GF, Lee VA, Prince AM, et al. Hepatitis B immune globulin for \naccidental exposures among medical personnel: final report of a multicenter \ncontrolled trial. J Infect Dis 1978;138:625–38. \n\t83.\tPrince AM, Szmuness W, Mann MK, et al. Hepatitis B immune globulin: \nfinal report of a controlled, multicenter trial of efficacy in prevention of \ndialysis-associated hepatitis. J Infect Dis 1978;137:131–44. \n\t84.\tPrince AM, Szmuness W, Mann MK, et al. Hepatitis B “immune” \nglobulin: effectiveness in prevention of dialysis-associated hepatitis. \nN Engl J Med 1975;293:1063–7.",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 84,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_85",
    "document_id": "rr6210",
    "text": "N Engl J Med 1975;293:1063–7. \n\t85.\tSeeff LB, Wright EC, Zimmerman HJ, et al. Type B hepatitis after needle-\nstick exposure: prevention with hepatitis B immune globulin. Final report \nof the Veterans Administration Cooperative Study. Ann Intern Med \n1978;88:285–93. \n\t86.\tSeeff LB, Zimmerman HJ, Wright EC, et al. A randomized, double \nblind controlled trial of the efficacy of immune serum globulin for the \nprevention of post-transfusion hepatitis: a Veterans Administration \ncooperative study. Gastroenterology 1977;72:111–21.\n\t87.\tKrugman S, Giles JP, Hammond J. Viral hepatitis, type B (MS-2 strain) \nprevention with specific hepatitis B immune serum globulin. JAMA \n1971;218:1665–70. \n\t88.\tWauters JP, Leski M. Delayed hepatitis after treatment with hepatitis B",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 85,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_86",
    "document_id": "rr6210",
    "text": "1971;218:1665–70. \n\t88.\tWauters JP, Leski M. Delayed hepatitis after treatment with hepatitis B \nimmune serum globulin. BMJ 1976;2:19–20. \n\t89.\tZhou F, Euler GL, McPhee SJ, et al. Economic analysis of promotion \nof hepatitis B vaccinations among Vietnamese-American children and \nadolescents in Houston and Dallas. Pediatrics 2003;111:1289–96. \n\t90.\tCDC. Guideline for infection control in health care personnel, 1998. \nAvailable at http://www.cdc.gov/hicpac/pdf/infectcontrol98.pdf.\n\t91.\tBolyard EA, Tablan OC, Williams WW, et al. Guideline for infection \ncontrol in healthcare personnel, 1998: Hospital Infection Control \nPractices Advisory Committee. Infect Control Hosp Epidemiol \n1998;19:407–63. \n\t92.\tEnfield KB, Sharapov U, Hall KK, et al. Transmission of hepatitis B",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 86,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_87",
    "document_id": "rr6210",
    "text": "1998;19:407–63. \n\t92.\tEnfield KB, Sharapov U, Hall KK, et al. Transmission of hepatitis B \nvirus from an orthopedic surgeon with a high viral load. Clin Infect Dis \n2013;56:218–24. \nRecommendations and Reports\nMMWR  /  December 20, 2013  /  Vol. 62  /  No. 10\t\n19\nExpert Panel Members\nDouglas Campos-Outcalt, MD, University of Arizona College of Medicine, Phoenix, Arizona; Alexis Elward, MD, Washington University School of \nMedicine, St Louis, Missouri; Kathleen Harriman, PhD, California Department of Public Health, Richmond, California; Samuel Katz, MD, Duke University, \nDurham, North Carolina; Harry Keyserling, MD, Emory University School of Medicine, Atlanta, Georgia; Thomas Koinis, MD, Duke University, Oxford,",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 87,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_88",
    "document_id": "rr6210",
    "text": "North Carolina; Susan Lett, MD, Massachusetts Department of Public Health, Boston, Massachusetts; Brian McMahon, MD, Alaska Native Tribal Health \nConsortium, Anchorage, Alaska; Amy Middleman, MD, Baylor College of Medicine, Houston, Texas; David A. Nace, MD, American Medical Directors \nAssociation, Columbia, Maryland; Mark Sawyer, MD, University of California at San Diego, California; Brenna Simons, PhD, Alaska Native Tribal Health \nConsortium, Anchorage, Alaska; Jonathan Temte, MD, PhD, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin; James \nTurner, MD, University of Virginia School of Medicine, Charlottesville, Virginia; David Weber, MD, Society for Healthcare Epidemiology of America,",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 88,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_89",
    "document_id": "rr6210",
    "text": "University of North Carolina, Chapel Hill, North Carolina; Marion Major, PhD, Food and Drug Administration, Bethesda, Maryland; Marie A. de Perio, \nMD, National Institute for Occupational Safety and Health; Geoff Beckett, PA-C, Kathy Byrd, MD, Scott Holmberg, MD, Trudy V. Murphy, MD, Sarah \nSchillie, MD, Philip Spradling, MD, Eyasu Teshale, MD, Fujie Xu, MD, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention; Erin \nKennedy, DVM, National Center for Immunization and Respiratory Diseases; David Kuhar, MD, Cindy Weinbaum, MD, National Center for Emerging \nand Zoonotic Infectious Diseases.\nDisclosure of Competing Interests",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 89,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_90",
    "document_id": "rr6210",
    "text": "and Zoonotic Infectious Diseases.\nDisclosure of Competing Interests\nThe developers of these guidelines wish to disclose that they have no financial interests or other relationships with the manufacturers of commercial products \nor suppliers of commercial services related to vaccines including any related to hepatitis B vaccines, with the following exceptions: David Weber, MD, wishes \nto disclose that he served as a consultant and on a speakers’ bureau, whether paid or unpaid (e.g., travel related reimbursement, honoraria), for the following \nvaccine manufacturers: Merck, Sanofi, and Pfizer pharmaceutical companies. Amy B. Middleman, MD, also wishes to disclose that she received grant funding \nfrom the following pharmaceutical companies:  MedImmune, Sanofi, and Merck.\n \n \n \nISSN: 1057-5987",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 90,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_91",
    "document_id": "rr6210",
    "text": "from the following pharmaceutical companies:  MedImmune, Sanofi, and Merck.\n \n \n \nISSN: 1057-5987\nThe Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free \nof charge in electronic format. To receive an electronic copy each week, visit MMWR’s free subscription page at http://www.cdc.gov/mmwr/mmwrsubscribe.\nhtml. Paper copy subscriptions are available through the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; \ntelephone 202-512-1800.\nAddress all inquiries about the MMWR Series, including material to be considered for publication, to Editor, MMWR Series, Mailstop E-90, CDC, 1600 \nClifton Rd., N.E., Atlanta, GA 30333 or to mmwrq@cdc.gov.",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 91,
      "total_chunks": 93
    }
  },
  {
    "chunk_id": "rr6210_chunk_92",
    "document_id": "rr6210",
    "text": "Clifton Rd., N.E., Atlanta, GA 30333 or to mmwrq@cdc.gov. \nAll material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.\nUse of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.\nReferences to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations \nor their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of these sites. URL addresses \nlisted in MMWR were current as of the date of publication.",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "2\nNA\nNA",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 92,
      "total_chunks": 93
    }
  }
]